Rituximab (Rituxan/MabThera; Biogen Idec/Genentech/Roche), a chimeric anti-CD20 monoclonal antibody, was tipped to be the first therapy approved for SLE in decades, but it failed to meet the ...

an allogeneic CAR-T therapy targeting CD19/CD20, has administered at the starting dose specified in the clinical protocol to the first patient with systemic lupus erythematosus (SLE) in an ...

Roche's anti-CD20 antibody Gazyva has been on the ... to treat kidney disease caused by the autoimmune disorder systemic lupus erythematosus (SLE). The US regulator has started a review of ...

as the company targets the billion-dollar lupus market for its CD20-targeting drug Gazyva (obinutuzumab). While the market for systemic lupus erythematosus (SLE) and lupus nephritis therapies ...

Gazyva is the only anti-CD20 monoclonal antibody in a randomized ... childhood-onset idiopathic nephrotic syndrome and systemic lupus erythematosus (SLE), an autoimmune disease that commonly ...

Patient enrollment in SLE, SSc, idiopathic inflammatory myopathy ... In the Phase 1 GLEAN trial, ADI-001 was shown to target B-cells via an anti-CD20 CAR and demonstrated robust exposure and ...